Ten-year experience with transcatheter and surgical aortic valve replacement in Finland by Mäkikallio, Timo et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iann20
Annals of Medicine
ISSN: 0785-3890 (Print) 1365-2060 (Online) Journal homepage: https://www.tandfonline.com/loi/iann20
Ten-year experience with transcatheter and
surgical aortic valve replacement in Finland
Timo Mäkikallio, Maina P. Jalava, Annastiina Husso, Marko Virtanen, Teemu
Laakso, Tuomas Ahvenvaara, Tuomas Tauriainen, Pasi Maaranen, Eeva-
Maija Kinnunen, Sebastian Dahlbacka, Jussi Jaakkola, Juhani Airaksinen,
Vesa Anttila, Mikko Savontaus, Mika Laine, Tatu Juvonen, Antti Valtola, Peter
Raivio, Markku Eskola, Matti Niemelä & Fausto Biancari
To cite this article: Timo Mäkikallio, Maina P. Jalava, Annastiina Husso, Marko Virtanen, Teemu
Laakso, Tuomas Ahvenvaara, Tuomas Tauriainen, Pasi Maaranen, Eeva-Maija Kinnunen,
Sebastian Dahlbacka, Jussi Jaakkola, Juhani Airaksinen, Vesa Anttila, Mikko Savontaus, Mika
Laine, Tatu Juvonen, Antti Valtola, Peter Raivio, Markku Eskola, Matti Niemelä & Fausto Biancari
(2019) Ten-year experience with transcatheter and surgical aortic valve replacement in Finland,
Annals of Medicine, 51:3-4, 270-279, DOI: 10.1080/07853890.2019.1614657
To link to this article:  https://doi.org/10.1080/07853890.2019.1614657
© 2019 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 21 May 2019.
Submit your article to this journal Article views: 305
View Crossmark data Citing articles: 1 View citing articles 
ORIGINAL ARTICLE
Ten-year experience with transcatheter and surgical aortic valve
replacement in Finland
Timo M€akikallioa, Maina P. Jalavab , Annastiina Hussoc, Marko Virtanend, Teemu Laaksoe,
Tuomas Ahvenvaaraf, Tuomas Tauriainenf, Pasi Maaranend, Eeva-Maija Kinnunene, Sebastian Dahlbackae,
Jussi Jaakkolab, Juhani Airaksinenb , Vesa Anttilab, Mikko Savontausb, Mika Lainee, Tatu Juvonene,
Antti Valtolac, Peter Raivioe, Markku Eskolad, Matti Niemel€aa and Fausto Biancarib,f,g
aDepartment of Internal Medicine, Oulu University Hospital, Oulu, Finland; bHeart Center, Turku University Hospital and University of
Turku, Turku, Finland; cHeart Center, Kuopio University Hospital, Kuopio, Finland; dHeart Hospital, Tampere University Hospital,
Tampere, Finland; eHeart Center, Helsinki University Hospital, Helsinki, Finland; fDepartment of Surgery, Oulu University Hospital and
University of Oulu, Finland; gDepartment of Surgery, University of Turku, Turku, Finland
ABSTRACT
Aim: We investigated the outcomes of transcatheter (TAVR) and surgical aortic valve replace-
ment (SAVR) in Finland during the last decade.
Methods: The nationwide FinnValve registry included data from 6463 patients who underwent
TAVR or SAVR with a bioprosthesis for aortic stenosis from 2008 to 2017.
Results: The annual number of treated patients increased three-fold during the study period.
Thirty-day mortality declined from 4.8% to 1.2% for TAVR (p¼ .011) and from 4.1% to 1.8% for
SAVR (p¼ .048). Two-year survival improved from 71.4% to 83.9% for TAVR (p< .001) and from
87.2% to 91.6% for SAVR (p¼ .006). During the study period, a significant reduction in moder-
ate-to-severe paravalvular regurgitation was observed among TAVR patients and a reduction of
the rate of acute kidney injury was observed among both SAVR and TAVR patients. Similarly,
the rate of red blood cell transfusion and severe bleeding decreased significantly among SAVR
and TAVR patients. Hospital stay declined from 10.4 ±8.4 to 3.7±3.4 days after TAVR (p< .001)
and from 9.0 ± 5.9 to 7.8±5.1 days after SAVR (p< .001).
Conclusions: In Finland, the introduction of TAVR has led to an increase in the invasive treat-
ment of severe aortic stenosis, which was accompanied by improved early outcomes after
both SAVR and TAVR.
Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT03385915
KEY MESSAGES
 This study demonstrated that the introduction of transcatheter aortic valve replacement has
led to its widespread use as an invasive treatment for severe aortic stenosis.
 Early and 2-year survival after transcatheter and surgical aortic valve replacement has
improved during past decade.
 Transcatheter aortic valve replacement has fulfilled its previously unmet clinical needs and has
surpassed surgical aortic valve replacement as the most common invasive treatment for aor-
tic stenosis.
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In the field of structural heart disease, transcatheter
aortic valve replacement (TAVR) occupies currently
a significant position as a valid invasive treatment
option for aortic valve stenosis (AS). Since the first
TAVR procedure in 2002 [1], it has rapidly grown as
a treatment of choice for a large proportion of
AS patients. It is currently recommended and FDA
approved treatment option for AS among inoperable
patients and high-risk patients as well as patients
with intermediate operative risk [2–8]. Furthermore,
preliminary data suggest that catheter approaches
may be comparable to surgery even in low-risk
patients [9]. To date, TAVR has been widely adopted
across the world and the number of patients
CONTACT Timo M€akikallio timo.makikallio@ppshp.fi Department of Internal Medicine, Oulu University Hospital, Oulu, Finland
 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-
nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed,
or built upon in any way.
ANNALS OF MEDICINE
2019, VOL. 51, NOS. 3–4, 270–279
https://doi.org/10.1080/07853890.2019.1614657
undergoing this procedure has increased rapidly dur-
ing last few years in the whole western hemi-
sphere [10].
Since TAVR has dramatically transformed the treat-
ment of symptomatic AS worldwide, we created a
national database to investigate the outcomes of
TAVR and SAVR treatments in Finland during past dec-
ade. The purpose of this national database is to detect
possible trends and changes in survival as well as in
numbers of untoward complications. Also changes in
patient clinical characteristics during the years were of
particular interest. We anticipated that although this
therapy was initially used to treat inoperable and
high-risk patients, improved procedural techniques as
well as dedicated pre-evaluation of the patient has led
to excellent consisted results with low morbidity and
mortality among TAVR patients with intermediate risk
as well as among SAVR patients.
Materials and methods
Study population
The FinnValve registry is a nationwide registry
(ClinicalTrials.gov Identifier: NCT03385915), which
retrospectively collects data from consecutive and
unselected patients who underwent TAVR or SAVR
with a bioprosthesis for severe AS at all five Finnish
university hospitals (Helsinki, Kuopio, Oulu, Tampere
and Turku) from January 2008 to November 2017.
During the study period, only these five university
hospitals performed TAVR and SAVR procedures. A
small number of TAVR procedures have been per-
formed in three central hospitals during a short
period of time during which this procedure was tem-
porarily allowed by the national authorities. Similarly,
a small number of SAVR procedures were performed
in a central hospital not performing TAVR proce-
dures. Data from patients treated in central hospitals
were not collected in to this registry, because these
procedures were performed outside a heart team
environment and this might have introduced bias in
to the results.
This study was approved by and a waiver for the
requirement of informed consent was obtained from
the Institutional Review Board of each participating
centre. The inclusion criteria for this registry were as
follows: (1) AS with or without aortic valve regurgita-
tion; (2) patients aged >18 years; and (3) primary
TAVR or SAVR with a bioprosthesis with or without
concomitant coronary revascularization. The exclu-
sion criteria of this study were as follows: (1) any
prior TAVR or surgical intervention on the aortic
valve; (2) concomitant major cardiac procedure on
the ascending aorta and/or other heart valves or
structures; (3) transcatheter or surgical procedure for
isolated aortic valve regurgitation; (4) acute endocar-
ditis; and (5) SAVR with a mechanical
valve prosthesis.
This nationwide registry was planned during sev-
eral meetings of the main investigators, who devel-
oped an electronic case report form which was filled
by clinicians and research nurses with specific experi-
ence in TAVR and SAVR procedures and their related
outcomes. No data from prior institutional datasets
contributed to this registry. This registry includes a
consecutive series of patients, whose operating code
referring to TAVR and/or SAVR with a bioprosthesis
were retrieved from Institutional administrative regis-
tries. The definition criteria of baseline, operative
and postoperative variables were prespecified and
listed in a table with a similar output of the elec-
tronic case report for rapid consultation by the
researchers, who were instructed before starting the
data collection to comply with these criteria. Data
underwent robust checking of its completeness and
quality. Data on mortality was retrieved from the
national registry Statistics Finland, which is based on
death certificates reviewed by local authorities.
Based on this, follow-up was considered complete
for all patients, but for two patients who were not
residing in Finland and whose follow-up was trun-
cated at hospital discharge.
Definition criteria of baseline risk factors
Baseline variables were defined according to the
EuroSCORE II criteria [11]. The operative risk of these
patients was stratified according to the EuroSCORE II
and STS [12] risk scores. Severe frailty was defined
according to the Geriatric Status Scale (GSS) and herein
is defined as GSS grades 2–3 as proposed by Rockwood
et al. [13]. Coronary artery disease was defined as any
stenosis 50% of the main coronary branches.
Outcome measures
The primary outcome of this study was 30-day mortal-
ity. The secondary outcomes were stroke, postopera-
tive use of intra-aortic balloon pump or extracorporeal
membrane oxygenation, conversion to cardiac surgery,
coronary artery occlusion, aortic annulus rupture,
aortic dissection/rupture, major vascular complication,
red blood cell transfusion, severe bleeding, resternot-
omy for bleeding, moderate-to-severe paravalvular
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regurgitation, implantation of permanent pace-maker,
severe acute kidney injury, atrial fibrillation, postoper-
ative length of stay in the hospital where the index
procedure was performed and 2-year survival (includ-
ing only patients operated from 2008 and 2015, i.e.
those with at least 2 years of follow-up). The length
of stay in the intensive care unit was not considered
in this analysis as an end-point because of inter-insti-
tutional differences in the organizational program of
postoperative care of TAVR patients. All the aforemen-
tioned adverse events, but mortality were recorded
only during the index hospitalization. The postproce-
dural echocardiographic findings of paravalvular
regurgitation were not adjudicated by a core lab and
its severity was graded before discharge by the treat-
ing physicians. Stroke was defined according to the
Valve Academic Research Consortium-2 (VARC-2) def-
inition criteria [14] as any focal or global neurological
deficit lasting 24 h or longer with a new brain infarct
or haemorrhage detected at neuroimaging, or a
neurological deficit resulting in death during the
index hospitalization. Severe bleeding was defined as
transfusion of more than 4 units of red blood cells
and/or any operation for excessive bleeding. Severity
of bleeding and major vascular complications were
defined also according to the VARC-2 definition crite-
ria [14]. Stage-3 acute kidney injury was defined as
according to the KDIGO classification criteria as any
increase in serum creatinine 3.0 times the baseline
level or serum creatinine increase 353.65lmol/l dur-
ing the hospital stay and/or de novo renal replace-
ment therapy during the hospital stay [14,15].
Figure 1. Study flowchart and annual number of transcatheter (TAVR) and surgical aortic valve replacement (SAVR) along the
study period.
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Statistical analysis
Statistical analysis was performed using SPSS v. 25.0
statistical software (IBM Corporation, New York, USA).
Comparative analysis of the TAVR and SAVR
cohorts were performed using the Mann–Whitney,
the Chi-square and the Fisher exact tests. Trends over
time were plotted and analyzed across the 10 years
intervals using the Mantel–Haenszel linear-by-linear
(LLA) association chi-squared test for trend and linear
regression with year categories regressed as an ordinal
variable. Differences in the long-term survival were
evaluated by the Kaplan-Meier method with the log-
rank test. A p< .05 was set for statistical significance.






Age, mean (years) 81.2 ± 6.6 75.1 ± 6.5 <.0001
Female, n (%) 1172 (55.0) 2026 (46.8) <.0001
Body mass index, mean (kg/m2) 27.1 ± 4.8 27.7 ± 4.8 <.0001
Hemoglobin, mean (mg/L) 125 ± 16 132 ± 15 <.0001
eGFR, mean (mL/min/1.73 m2) 65 ± 23 76 ± 22 <.0001
Active malignancy, n (%) 84 (3.9) 60 (1.4) <.0001
Diabetes, n (%) 605 (28.4) 1154 (26.6) .133
Stroke, n (%) 247 (11.6) 299 (6.9) <.0001
Pulmonary disease, n (%) 456 (21.4) 642 (14.8) <.0001
Oxygen therapy, n (%) 14 (0.7) 16 (0.4) .109
Frailty GSS grades 2–3, n (%) 318 (14.9) 107 (2.5) <.0001
Extracardiac arteriopathy, n (%) 412 (19.3) 539 (12.4) <.0001
LVEF 50%, n (%) 596 (28.0) 909 (21.0) <.0001
Atrial fibrillation, n (%) 932 (43.8) 955 (22.0) <.0001
NYHA class 4, n (%) 244 (11.5) 453 (10.5) .223
SPAP, n (%) <.0001
31–55mmHg 853 (40.0) 1526 (35.2)
>55mmHg 286 (13.4) 305 (7.0)
Moderate-severe mitral valve regurgitation, n (%) 288 (14.3) 256 (6.5) <.0001
Porcelain aorta, n (%) 124 (5.8) 15 (0.3) <.0001
Recent myocardial infarction, n (%) 49 (2.3) 312 (7.2) <.0001
Acute heart failure 60 days/critical preop. state, n (%) 253 (11.9) 501 (11.6) .710
Coronary artery disease, n (%) 603 (28.3) 1970 (45.5) <.0001
Prior PCI, n (%) 467 (21.9) 405 (9.3) <.0001
Prior cardiac surgery 431 (20.2) 97 (2.2) <.0001
Permanent pace-maker, n (%) 208 (9.8) 174 (4.0) <.0001
Emergency procedure, n (%) 6 (0.3) 59 (1.4) <.0001
Bicuspid aortic valve, n (%) 114 (5.4) 920 (21.0) <.0001
Concomitant PCI/CABG, n (%) 119 (5.6) 1835 (42.3) <.0001
EuroSCORE II, mean (%) 7.2 ± 7.4 4.2 ± 5.5 <.0001
STS Score, mean (%) 4.6 ± 3.3 3.0 ± 2.9 <.0001
Continuous variables are reported as means ± standard deviation. Categorical variables as counts and percentages. Clinical variables are according to the
EuroSCORE II definition criteria. SAVR: surgical aortic valve replacement; TAVR: transcatheter aortic valve replacement; eGFR: glomerular filtration esti-
mated according to the MDRD equation; LVEF: left ventricular ejection fraction; Frailty, GSS grades 2–3; SPAP: systolic pulmonary artery pressure; PCI:
percutaneous coronary intervention; CABG: coronary artery bypass grafting.
Figure 2. Frequencies of transcatheter (TAVR) and surgical aortic valve replacement (SAVR) along the study period.
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Results
The FinnValve registry includes data from 6 463 patients
who underwent primary TAVR (2 130 patients) and
SAVR (4 333 patients) with a bioprothesis for severe AS
(Figure 1). Among the TAVR prostheses, 1689 were
mechanically expanding valves (79.4%) and 439 were
self-expandable valves (20.6%, data on TAVR prosthesis
was missing in two patients). Third-generation TAVR
prosthesis were implanted in 1451 patients (68.2%).
Among the SAVR prostheses, 126 were sutureless pros-
theses (0.3%) and 4308 (99.5%) were stented valve pros-
theses (data on SAVR prosthesis was missing in two
patients). Clinical characteristics of patients who
underwent TAVR or SAVR are presented in Table 1.
Nationwide progressive increase in number of invasively
treated AS patients during whole study period was evi-
dent (Figure 1). In Finland TAVR surpassed SAVR as
most prevalent treatment option in 2016 (Figure 2).
During 10-year study period, the mean STS pre-
operative risk score declined from 6.5 ± 5.7% to
4.1 ± 3.1% level for TAVR (p< .001) and from 3.1 ± 2.3
to 2.2 ± 1.5% for SAVR (p< .001) (Figure 3). The 30-day
mortality of decreased from 4.8% to 1.2% (75%
decrease, p¼ .011) for TAVR and from 4.1% to 1.8%
(56% decrease, p¼ .048) for SAVR (Figure 4). This trend
was evident during second half of the study period
Figure 3. Operative risk stratified by the Society of Thoracic Surgeons (STS) score in patients who underwent transcatheter (TAVR)
or surgical aortic valve replacement (SAVR) along the study period.
Figure 4. Observed and predicted 30-day mortality by the Society of Thoracic Surgeons (STS) score in patients who underwent
transcatheter (TAVR) or surgical aortic valve replacement (SAVR) along the study period. P-values are from the linear-by-linear
association test.
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and led to a significant decrease of the overall 30-day
mortality (p¼ .001) (Figure 4). Two-year survival
improved from 71.4% to 83.9% for TAVR patients and
from 87.2% to 91.6% for SAVR patients (Figure 5).
Thirty-day, 1-, 3, and 5-year survival rates after TAVI
were 97.1%, 90.6%, 73.0% and 51.9%, and after SAVR
96.4%, 92.9%, 86.9% and 78.7%, respectively (log-rank
test, p< .0001).
Early adverse events are summarized in Table 2.
Conversion to open surgery was required in 13 patients
(0.6%) who underwent TAVR and the related 30-day
and 1-year mortality were 38.5% and 48.7%, respect-
ively (p< .0001 compared to patients not requiring con-
version to cardiac surgery). The reasons for conversion
to cardiac surgery were as follows: aortic root rupture
in four patients, wire perforation of the left ventricle in
in four patients, TAVR prosthesis migration in three
patients, bleeding from pace-maker lead perforation
of the innominate vein in one patient and severe
bleeding from unspecified site in one patient.
Figure 5. Two years survival in patients who underwent transcatheter (TAVR) or surgical aortic valve replacement (SAVR) from
2018 to 2015. p-Values are from the linear-by-linear association test.







30-day death, (%) 62 (2.9) 158 (3.6) .125
Stroke, n (%) 53 (2.5) 165 (3.8) .006
Postop. IABP/ECMO, n (%) 4 (0.2) 80 (1.8) <.0001
Conversion to cardiac surgery, n (%) 13 (0.6) – –
Coronary ostium occlusion, n (%) 8 (0.4) 10 (0.2) .320
Aortic annulus rupture, n (%) 10 (0.5) 8 (0.2) .047
Aortic dissection/rupture 17 (0.8) 31 (0.7) .716
Major vascular complication, n (%) 191 (9.0) 69 (1.6) <.0001
RBC trasfusion, n (%) 403 (19.2) 3010 (70.4) <.0001
RBC transfusion, mean (units) 0.6 ± 1.7 3.0 ± 3.8 <.0001
RBC transfusion, >4 units 76 (3.6) 926 (21.7) <.0001
Resternotomy for bleeding, n (%) 30 (1.4) 351 (8.1) <.0001
Severe bleeding,a n (%) 116 (5.5) 1033 (24.1) <.0001
VARC-2 bleeding events <.0001
Major, n (%) 567 (26.7) 1564 (36.2)
Life-threatening, n (%) 167 (7.9) 2597 (60.0)
KDIGO acute kidney injury grades 3,b n (%) 21 (1.0) 127 (3.0) <.0001
Renal replacement therapy, n (%) 30 (1.4) 113 (2.6) .002
Moderate-severe paravalvular regurgitation, n (%) 79 (3.7) 29 (0.7) <.0001
Atrial fibrillation,c n (%) 160 (13.4) 1645 (48.7)) <.0001
Permanent pacemaker, n (%) 185 (8.7) 170 (3.9) <.0001
Hospital stay, mean (days) 5.5 ± 5.0 8.3 ± 6.4 <.0001
Continuous variables are reported as means ± standard deviation. Categorical variables as counts and percentages. a, it refers to transfusion of more than
4 units of red blood cells and/or operation for excessive bleeding; b, it excludes patients with estimated glomerular filtration rate <15mL/min/1.73 m2
or dialysis; c, it excludes patients with preoperative atrial fibrillation. TAVR: transcatheter aortic valve replacement; SAVR: surgical aortic valve replace-
ment; IABP: intraaortic balloon pump; ECMO: extracorporeal membrane oxygenation; RBC: red blood cells; VARC-2: Valve Academic Research Consortium-
2; KDIGO: Kidney Disease: Improving Global Outcomes.
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The number of complications declined during past
decade among both operation modalities. A significant
reduction in moderate-to-severe paravalvular regurgita-
tion was observed among TAVR patients and a reduc-
tion of the rate of stage 3 acute kidney injury was
observed among both SAVR and TAVR patients
(Figure 6). Similarly, the rate of red blood cell transfu-
sion and severe bleeding (transfusion of >4 units of red
blood cells and/or operation for bleeding) decreased
significantly among SAVR and TAVR patients (Figure 7).
A trend toward reduction in stroke rate was observed
among TAVR patients during the study period. The
mean hospital stay declined from 10.4±8.4 to 3.7±3.4
days after TAVR and from 9.0±5.9 to 7.8 ±5.1 days after
SAVR (Figure 6).
Discussion
The main findings of the present study are that: [1]
the early and intermediate mortality in patients with
AS has decreased during past 5-year period among
TAVR treated patients as well as among SAVR treated
patients despite relatively stable overall preoperative
risk among this patient group; [2] in Finland, TAVR
is now extensively used for patients at high and
intermediate risk and it has surpassed SAVR as the
most common treatment strategy for severe AS; [3]
advanced technology of TAVR has led to reduced rates
of perioperative bleeding, stroke, severe acute kidney
injury and other procedural complications placing
TAVR now as an effective standardized procedure with
the safe and feasible treatment results for most
patients with symptomatic severe AS.
With over 500,000 TAVR patients treated to date
worldwide, indications for TAVR continue to widen.
Current estimates predict 200,000 annual candidates for
TAVR in 2020 [16]. TAVR is currently recommended for
inoperable and high-risk patients as well as for patients
with intermediate operative risk [17]. This retrospective
study confirms that also in Finland this trend is evident
and likely to continue. Improved survival of current
TAVR operations nationwide, reduction of major and
minor complications as well as decreased demand for
postoperative care will likely cause higher TAVR
implantation rate in the future among patients with
severe AS. TAVR treatment surpassed SAVR as the most
common treatment for severe AS in 2016 in Finland.
The same shift has occurred in 2014 in Germany [18].
Adoption rates of this therapy vary from country to
country as a result of interpretation differences of the
results of scientific clinical trials as well as heteroge-
neous reimbursement programs [19–21].
Complication rates of TAVR operations has rapidly
declined and are currently comparable or even better
(kidney injury, severe bleeding) than SAVR, despite the
older age and higher comorbidities of TAVR patients
relative to SAVR patients. Severe TAVR specific compli-
cations, like annular rupture, are becoming very rare
Figure 6. Incidence of stroke, moderate-to-severe paravalvular regurgitation, acute kidney injury stage 3 and length of hospital
stay after transcatheter (TAVR) and surgical aortic valve replacement (SAVR) along the study period. P-values are from the linear-
by-linear association test.
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due to improved implantation and imaging techniques
and development of TAVR devices. However, a word
of caution is in place while reaching this therapy to
low risk patients. Several issues will play a key role in
expanding TAVR indication in healthier individuals.
Particularly issues like valve durability, need for per-
manent pacemaker, valve performance as well as opti-
mal antithrombotic or anticoagulation medication are
questions needed to be answered when expanding
TAVR treatment to low-risk patient populations [22].
Since the short-term TAVR results in procedure
mortality, stroke, valve performance and vascular com-
plications has been excellent [2–8], the main attention
is directed now to long-term durability of TAVR valves.
Most SAVR bio-prosthesis has a 10-year freedom from
reoperation that is above 97% [23]. Long-term survival
free of structural valve degeneration is a well-known
fact for SAVR while it still is somewhat unclear for
TAVR. A report from 5-year follow-up from PARTNER I
trial revealed excellent durability without significant
structural valve degeneration up to 5 years [24]. A
meta-analysis confirmed the good long-term durability
of TAVR devices [25]. However, the long-term durabil-
ity is of pivotal importance in younger patient with a
life-expectance greater than 10 years when TAVR or
SAVR options are considered. Another major practical
issue which needs to be solved is whether TAVR is to
replace SAVR among younger patient population
because of a relatively high permanent pacemaker
implantation rate for some TAVR devices [26]. Heart
conduction disturbances are the most common com-
plication of TAVR. Need for permanent pacemaker
varies in relation with the valve type used. Even if
mortality has not been increased in patients
Figure 7. Rates of red blood cell (RBC) transfusion and of transfusion of >4 units of RBC and/or operation for excessive bleeding
in patients who underwent transcatheter (TAVR) or surgical aortic valve replacement (SAVR). P-values are from the linear-by-linear
association test.
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undergoing TAVR or SAVR and requiring permanent
pacemaker implantation, the long-term effects of hav-
ing permanent pacemaker particularly in younger
patient populations may be significant. In the present
study, implantation of permanent pacemaker was
more frequent among TAVR patients than among
SAVR patients. However, with modern devices very
low permanent pacemaker implantation rates have
been reported [27]. Ongoing clinical trials currently in
progress for low-risk patients as well as results from
long-term follow-ups of previous trials and large regis-
tries will clarify the role of TAVR and SAVR operations
among low risk younger patients in not too distant
future [28–29].
Despite the excellent results in this nationwide
database and other large registries as well as several
randomized clinical trials with positive results [2–9],
resistance from surgeons [10] and the abovemen-
tioned lack of randomized long-term data to provide
solid information concerning valve durability will cur-
rently curb TAVR adoption rate. Although extensive
laboratory testing of used devices has been con-
ducted, long-term durability of TAVR devices in vivo
remains somewhat unclear and reliable long-term out-
come data over 10 years concerning durability is not
currently available. Therefore, routine use of TAVR in
younger patients may not be feasible beyond the lim-
its of randomized controlled clinical trials.
Although it has been postulated that TAVR might
become the standard of care for most patients with
severe AS in near future, accounting for even 90% of
all aortic valve replacement procedures [30], SAVR
will remain the treatment of choice for various patient
groups, such as patients with coexistent severe multi-
vessel coronary artery disease, diseases of the ascend-
ing aorta, and infective endocarditis. Therefore,
development of SAVR procedural techniques is also of
pivotal importance. This scenario may become valid, if
ongoing clinical trials with low-risk patients will pro-
vide positive results for TAVR treatment.
Limitations
The present study has limitations inherent to all retro-
spective analyses. First, the reasons for treatment allo-
cation cannot be fully resolved and likely changed
along the study period. In this context, the direction
and magnitude of bias cannot be determined.
However, this nationwide registry is mainly descriptive
in nature offering an excellent view to evaluate TAVR
and SAVR operations and their results independently.
Conclusions
This nationwide registry demonstrated that the intro-
duction of TAVR has led to a widespread use of inva-
sive treatment for severe AS, which was accompanied
by improved early outcomes after both SAVR and
TAVR. During the past decade, TAVR has fulfilled its
previously unmet clinical needs and has surpassed
SAVR as the most common invasive treatment for AS.
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